Cargando…

Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase

How to improve the efficacy and reverse the resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as erlotinib, remains a major challenge in the targeted therapy of lung adenocarcinoma with EGFR-activating mutation. Phosphoglycerate dehydrogenase (PHGDH) is the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dong, Jiang-Kai, Lei, Hui-Min, Liang, Qian, Tang, Ya-Bin, Zhou, Ye, Wang, Yang, Zhang, Shengzhe, Li, Wen-Bin, Tong, Yunguang, Zhuang, Guanglei, Zhang, Liang, Chen, Hong-Zhuan, Zhu, Liang, Shen, Ying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5858502/ https://www.ncbi.nlm.nih.gov/pubmed/29556358 http://dx.doi.org/10.7150/thno.23177

Ejemplares similares

Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase: Erratum
por: Dong, Jiang-Kai, et al.
Publicado: (2021)

D-3-Phosphoglycerate Dehydrogenase
por: Grant, Gregory A.
Publicado: (2018)

Targeting phosphoglycerate dehydrogenase in multiple myeloma
por: Elsaadi, Samah, et al.
Publicado: (2021)

Aldehyde dehydrogenase 1A1 confers erlotinib resistance via facilitating the reactive oxygen species-reactive carbonyl species metabolic pathway in lung adenocarcinomas
por: Lei, Hui-Min, et al.
Publicado: (2019)

The Role of D-3-Phosphoglycerate Dehydrogenase in Cancer
por: Zhao, Xiaoya, et al.
Publicado: (2020)

Aldehyde dehydrogenase 1A1 confers erlotinib resistance via facilitating the reactive oxygen species-reactive carbonyl species metabolic pathway in lung adenocarcinomas: Erratum
por: Lei, Hui-Min, et al.
Publicado: (2023)

Expanding the clinical spectrum of 3-phosphoglycerate dehydrogenase deficiency
por: Tabatabaie, L., et al.
Publicado: (2010)

Phosphoglycerate dehydrogenase is dispensable for breast tumor maintenance and growth
por: Chen, Jinyun, et al.
Publicado: (2013)

Impact of EGFR Mutation Detection Methods on the Efficacy of Erlotinib in Patients with Advanced EGFR-Wild Type Lung Adenocarcinoma
por: Tseng, Jeng-Sen, et al.
Publicado: (2014)

Phosphoglycerate dehydrogenase is a novel predictor for poor prognosis in gastric cancer
por: Xian, Yun, et al.
Publicado: (2016)

Amplification of phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis
por: Locasale, Jason W, et al.
Publicado: (2012)

Human Phosphoglycerate Dehydrogenase Produces the Oncometabolite d-2-Hydroxyglutarate
por: Fan, Jing, et al.
Publicado: (2014)

Phosphoglycerate Dehydrogenase: Potential Therapeutic Target and Putative Metabolic Oncogene
por: Zogg, Cheryl K.
Publicado: (2014)

A novel small-molecule inhibitor of 3-phosphoglycerate dehydrogenase
por: Mullarky, Edouard, et al.
Publicado: (2016)

Phosphoglycerate dehydrogenase positively regulates the proliferation of chicken muscle cells
por: Wang, Han, et al.
Publicado: (2022)

Biochemical and Biophysical Characterization of Recombinant Human 3-Phosphoglycerate Dehydrogenase
por: Murtas, Giulia, et al.
Publicado: (2021)

Designing Cyclic-Constrained Peptides to Inhibit Human Phosphoglycerate Dehydrogenase
por: Qing, Xiaoyu, et al.
Publicado: (2023)

Gemcitabine Overcomes Erlotinib Resistance in EGFR-Overexpressing Cancer Cells through Downregulation of Akt
por: Bartholomeusz, Chandra, et al.
Publicado: (2011)

Stromal NADH supplied by PHOSPHOGLYCERATE DEHYDROGENASE3 is crucial for photosynthetic performance
por: Höhner, Ricarda, et al.
Publicado: (2021)

Phosphatidic acid suppresses autophagy through competitive inhibition by binding GAPC (glyceraldehyde-3-phosphate dehydrogenase) and PGK (phosphoglycerate kinase) proteins
por: Guan, Bin, et al.
Publicado: (2022)

Advanced lung adenocarcinoma in an EGFR-positive patient treated with Erlotinib for 52 months
por: Gonçalves, Ivone, et al.
Publicado: (2013)

Diversified amino acid-mediated allosteric regulation of phosphoglycerate dehydrogenase for serine biosynthesis in land plants
por: Okamura, Eiji, et al.
Publicado: (2021)

Structure–Activity Relationships (SARs) of α-Ketothioamides as Inhibitors of Phosphoglycerate Dehydrogenase (PHGDH)
por: Spillier, Quentin, et al.
Publicado: (2020)

Phosphoglycerate dehydrogenase induces glioma cells proliferation and invasion by stabilizing forkhead box M1
por: Liu, Jinlong, et al.
Publicado: (2012)

Human phosphoglycerate dehydrogenase produces the oncometabolite D-2-hydroxyglutarate and promotes histone methylation
por: Fan, Jing, et al.
Publicado: (2014)

An epitope tag alters phosphoglycerate dehydrogenase structure and impairs ability to support cell proliferation
por: Mattaini, Katherine R, et al.
Publicado: (2015)

Identification and Biochemical Characterization of the Serine Biosynthetic Enzyme 3-Phosphoglycerate Dehydrogenase in Marchantia polymorpha
por: Akashi, Hiromichi, et al.
Publicado: (2018)

Novel regulatory mechanism of serine biosynthesis associated with 3-phosphoglycerate dehydrogenase in Arabidopsis thaliana
por: Okamura, Eiji, et al.
Publicado: (2017)

Identification of Novel Natural Inhibitors to Human 3-Phosphoglycerate Dehydrogenase (PHGDH) for Cancer Treatment
por: Sadiqa, Ayesha, et al.
Publicado: (2022)

Inhibition of Phosphoglycerate Dehydrogenase Radiosensitizes Human Colorectal Cancer Cells under Hypoxic Conditions
por: Van de Gucht, Melissa, et al.
Publicado: (2022)

Comparison of first-generation EGFR-TKIs (gefitinib, erlotinib, and icotinib) as adjuvant therapy in resected NSCLC patients with sensitive EGFR mutations
por: He, Qihua, et al.
Publicado: (2021)

Chronopharmacology and Mechanism of Antitumor Effect of Erlotinib in Lewis Tumor-Bearing Mice
por: Wang, Peipei, et al.
Publicado: (2014)

Effects of erlotinib therapy on [(11)C]erlotinib uptake in EGFR mutated, advanced NSCLC
por: Bahce, Idris, et al.
Publicado: (2016)

Structural insights into the enzymatic activity and potential substrate promiscuity of human 3-phosphoglycerate dehydrogenase (PHGDH)
por: Unterlass, Judith E., et al.
Publicado: (2017)

Dramatic Response to Teriprilumab and Anlotinib Combination Therapy in a patient with EGFR-Mutant Lung Adenocarcinoma Who Experienced Small-Cell Transformation−Mediated Erlotinib Resistance After Failure of Chemotherapy
por: Zhou, Yuling, et al.
Publicado: (2020)

Plasma-derived phosphoglycerate mutase 5 as a biomarker for Parkinson’s disease
por: Feng, Liang, et al.
Publicado: (2022)

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
por: Pao, William, et al.
Publicado: (2005)

A promising response to osimertinib in a patient with erlotinib-resistant lung adenocarcinoma with an uncommon EGFR mutation
por: Niwa, Hideyuki, et al.
Publicado: (2018)

Case report: primary resistance to osimertinib in erlotinib-pretreated lung adenocarcinoma with EGFR T790 M mutation
por: Zheng, Lin-Peng, et al.
Publicado: (2018)

Successful crizotinib monotherapy in EGFR-mutant lung adenocarcinoma with acquired MET amplification after erlotinib therapy
por: Yoshimura, Katsuhiro, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_gr7lbpre590690n9pj5c682vnk